BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is often recommended to carriers of deleterious breast cancer gene 1/2 (BRCA1/2) mutations in order to reduce their breast cancer risk by 50% and their ovarian cancer risk by approximately 95%. To evaluate the acceptance, timing, histopathology findings and follow-up results we retrospectively analyzed a cohort of BRCA1/2 mutation carriers who underwent risk-reducing salpingo-oophorectomies. METHODS: Between 1996 and 2009, 306 women who tested positive for a BRCA1 or BRCA2 mutation were counseled for preventive options. RRSO was recommended to all mutation carriers at age 40 or 5 years prior to the earliest occurrence of ovarian cancer in the family. Data from 175 BRCA mutation carriers (92 BRCA1 and 83 BRCA2), who decided to undergo a RRSO, were analyzed. Data were collected from study entry until recent follow-up. RESULTS: Fifty-seven percent of BRCA mutation carriers opted for RRSO. Mean age at time of surgery was 47 years. Overall, one occult carcinoma of the fallopian tube was detected at the time of surgery in a 57-year-old woman and one primary peritoneal carcinoma occurred 26 months after RRSO in a 59-year-old woman. CONCLUSION: Risk-reducing salpingo-oophorectomy is widely accepted. Recommendation of surgery at the age of 40 seems to be safe and the frequency of extraovarian primary peritoneal carcinoma after surgery is low.
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is often recommended to carriers of deleterious breast cancer gene 1/2 (BRCA1/2) mutations in order to reduce their breast cancer risk by 50% and their ovarian cancer risk by approximately 95%. To evaluate the acceptance, timing, histopathology findings and follow-up results we retrospectively analyzed a cohort of BRCA1/2 mutation carriers who underwent risk-reducing salpingo-oophorectomies. METHODS: Between 1996 and 2009, 306 women who tested positive for a BRCA1 or BRCA2 mutation were counseled for preventive options. RRSO was recommended to all mutation carriers at age 40 or 5 years prior to the earliest occurrence of ovarian cancer in the family. Data from 175 BRCA mutation carriers (92 BRCA1 and 83 BRCA2), who decided to undergo a RRSO, were analyzed. Data were collected from study entry until recent follow-up. RESULTS: Fifty-seven percent of BRCA mutation carriers opted for RRSO. Mean age at time of surgery was 47 years. Overall, one occult carcinoma of the fallopian tube was detected at the time of surgery in a 57-year-old woman and one primary peritoneal carcinoma occurred 26 months after RRSO in a 59-year-old woman. CONCLUSION: Risk-reducing salpingo-oophorectomy is widely accepted. Recommendation of surgery at the age of 40 seems to be safe and the frequency of extraovarian primary peritoneal carcinoma after surgery is low.
Authors: Xinglei Chai; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Peter J Hulick; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joanne L Blum; Susan M Domchek; Jinbo Chen; Timothy R Rebbeck Journal: Breast Cancer Res Treat Date: 2014-10-14 Impact factor: 4.872
Authors: Mark E Sherman; Marion Piedmonte; Phuong L Mai; Olga B Ioffe; Brigitte M Ronnett; Linda Van Le; Iouri Ivanov; Maria C Bell; Stephanie V Blank; Paul DiSilvestro; Chad A Hamilton; Krishnansu S Tewari; Katie Wakeley; Noah D Kauff; S Diane Yamada; Gustavo Rodriguez; Steven J Skates; David S Alberts; Joan L Walker; Lori Minasian; Karen Lu; Mark H Greene Journal: J Clin Oncol Date: 2014-09-08 Impact factor: 44.544
Authors: Janusz Menkiszak; Anita Chudecka-Głaz; Jacek Gronwald; Aneta Cymbaluk-Płoska; Aleksander Celewicz; Maria Świniarska; Małgorzata Wężowska; Ryszard Bedner; Dorota Zielińska; Paulina Tarnowska; Jerzy Jakubowicz; Zbigniew Kojs Journal: J Ovarian Res Date: 2016-02-29 Impact factor: 4.234
Authors: Y C Lee; M Bressel; P Grant; P Russell; C Smith; S Picken; S Camm; B E Kiely; R L Milne; S A McLachlan; M Hickey; M L Friedlander; J L Hopper; K A Phillips Journal: Fam Cancer Date: 2017-10 Impact factor: 2.375
Authors: Janusz Menkiszak; Anita Chudecka-Głaz; Aneta Cymbaluk-Płoska; Aleksander Celewicz; Zbigniew Kojs; Mariusz Szajda; Maria Świniarska; Ryszard Bedner; Anna Jurczak; Marta Celewicz; Monika Cieszyńska; Jan Lubiński; Jacek Gronwald Journal: Hered Cancer Clin Pract Date: 2019-03-14 Impact factor: 2.857
Authors: Inge T A Peters; Carina G J M Hilders; Cornelis F M Sier; Alexander L Vahrmeijer; Vincent T H B M Smit; J Baptist Trimbos; Peter J K Kuppen Journal: Arch Gynecol Obstet Date: 2016-03-05 Impact factor: 2.344
Authors: Jessica E van der Aa; Jacob P Hoogendam; Els S F Butter; Margreet G E M Ausems; René H M Verheijen; Ronald P Zweemer Journal: Fam Cancer Date: 2015-12 Impact factor: 2.375